Gene · 55
Papers3,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,704
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer. | Front Endocrinol (Lausanne) | 2023 | 37008945 | PubTator, text mining | PubMed |
| WGCNA combined with machine learning algorithms for analyzing key genes and immune cell infiltration in heart failure due to ischemic cardiomyopathy. | Front Cardiovasc Med | 2023 | 37008314 | PubTator, text mining | PubMed |
| Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer. | Front Genet | 2023 | 37007952 | PubTator, text mining | PubMed |
| Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis. | Am J Mens Health | 2023 | 37002863 | PubTator, text mining | PubMed |
| Intervertebral disc degeneration and how it leads to low back pain. | JOR Spine | 2023 | 36994466 | PubTator, text mining | PubMed |
| The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches. | Biomedicines | 2023 | 36979805 | PubTator, text mining | PubMed |
| Understanding Different Types of Followers' Engagement and the Transformation of Millennial Followers into Cosmetic Brand Evangelists. | Behav Sci (Basel) | 2023 | 36975295 | PubTator, text mining | PubMed |
| Prostate cancer bone metastases biology and clinical management (Review). | Oncol Lett | 2023 | 36960185 | PubTator, text mining | PubMed |
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). | J Immunother Cancer | 2023 | 36948505 | PubTator, text mining | PubMed |
| Potential Auxiliary Metabolic Capabilities and Activities Reveal Biochemical Impacts of Viruses in Municipal Wastewater Treatment Plants. | Environ Sci Technol | 2023 | 36947091 | PubTator, text mining | PubMed |
| Evidence for a Putative Isoprene Reductase in Acetobacterium wieringae. | mSystems | 2023 | 36943133 | PubTator, text mining | PubMed |
| The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. | Cell Biosci | 2023 | 36941697 | PubTator, text mining | PubMed |
| Progression in immunotherapy for advanced prostate cancer. | Front Oncol | 2023 | 36925917 | PubTator, text mining | PubMed |
| Research progress on non-protein-targeted drugs for cancer therapy. | J Exp Clin Cancer Res | 2023 | 36918935 | PubTator, text mining | PubMed |
| Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance. | Ann Rheum Dis | 2023 | 36918189 | PubTator, text mining | PubMed |
| The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy. | Front Immunol | 2023 | 36911717 | PubTator, text mining | PubMed |
| Mass Spectrometry-Based Untargeted Approaches to Reveal Diagnostic Signatures of Male Infertility in Seminal Plasma: A New Laboratory Perspective for the Clinical Management of Infertility? | Int J Mol Sci | 2023 | 36901856 | PubTator, text mining | PubMed |
| Recent Advances and Progress on Melanin: From Source to Application. | Int J Mol Sci | 2023 | 36901791 | PubTator, text mining | PubMed |
| Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. | Cancers (Basel) | 2023 | 36900202 | PubTator, text mining | PubMed |
| Vaccines as treatments for prostate cancer. | Nat Rev Urol | 2023 | 36879114 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55/papers?page=10